首页> 外文期刊>Advances in Microbiology >Bacterial Fecal Microbiota in Healthy Subjects and Inpatients with Clostridium difficile Infection
【24h】

Bacterial Fecal Microbiota in Healthy Subjects and Inpatients with Clostridium difficile Infection

机译:健康受试者和艰难梭菌感染患者的细菌粪便微生物群

获取原文
       

摘要

Clostridium difficile is a nosocomial enteric pathogen, considered the main etiological agent of antibiotic-associated diarrhea in hospitals. C. difficile is resistant to several antimicrobial agents used in empiric treatment protocols, which confers selective advantages to this species as compared with other members of the intestinal microbiota. The aim of this study was to evaluate and identify possible alterations of the intestinal microbiota population resulting from the use of antimicrobials associated with infections by C. difficile (CDI). Denaturing Gradient Gel Electrophoresis (DGGE) was used to evaluate fecal samples from two groups: healthy subjects and patients with C. difficile-associated diarrhea (CDAD). A decrease in bacterial diversity was highlighted by the low number of bands in samples from CDAD patients, compared with healthy subjects. This may indicate that antibiotic treatment would affect bacterial diversity, leading to a significant difference between the intestinal microbiota of these two groups, but further studies are still needed. Firmicutes and Verrucomicrobia phyla were detected mainly in healthy individuals, and these could be related to protection factors against the CDI. Klebsiella variicola/K. pneumoniae were found mostly in samples from CDI patients. This study shows the effects of antimicrobials and the CDI itself on human intestinal microbiota.
机译:艰难梭菌是一种医院内肠道病原体,被认为是医院中与抗生素有关的腹泻的主要病原体。艰难梭菌对经验治疗方案中使用的几种抗微生物剂具有抗性,与肠道菌群的其他成员相比,赋予该物种选择性的优势。这项研究的目的是评估和确定由于使用与艰难梭菌(CDI)感染相关的抗菌剂而引起的肠道菌群数量的可能变化。变性梯度凝胶电泳(DGGE)用于评估两组的粪便样品:健康受试者和艰难梭菌相关性腹泻(CDAD)患者。与健康受试者相比,CDAD患者样品中的条带数量少,突出了细菌多样性的降低。这可能表明抗生素治疗会影响细菌的多样性,从而导致这两组细菌的肠道菌群之间存在显着差异,但仍需要进一步的研究。主要在健康个体中检测到硬毛菌和Verrucomicrobia phyla,这可能与针对CDI的保护因子有关。水痘克雷伯氏菌/ K。肺炎多见于CDI患者的样本中。这项研究显示了抗菌剂和CDI本身对人体肠道菌群的影响。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号